Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.
Orchid Pharma, once abandoned by investors, is hitting a major milestone with its first novel antibiotic drug. The company outlicensed the experimental therapy to Germany’s Allecra Therapeutics, which has now secured crucial approvals from the US FDA and a European drug regulator. Developed by Indian scientists in 2008, the breakthrough aims to strengthen the global fight against bacterial infections.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
